Luceiro Capital Companies

ESEN

Real companies with freely usable public data: official annual reports of European listed companies (ESEF), SEC accounts and ECB exchange rates. No share prices, so there is no market capitalisation, P/E or EV/EBITDA.

Company sheet · analysis as of 21/10/2026

AbbVie Inc.

ABBV · Health care · Pharmaceuticals · US · reporting currency USD · LEI FR5LCKFTG8054YNNRU85

Share: XNYS · USD · US00287Y1091 · Price: No data: no share prices up to the analysis date

Reference period: H1 ended 30/06/2026, published on 03/08/2026

← Back to the ranking

Shareholder score without valuation

89

Coverage 67 %

Credit score

36

Coverage 67 %

Alerts

0

Screens passed: 0 of 1

Shareholder view

FactorValueCompared with PercentileWeightContribution
ROE Not meaningful — — 17 % —
Attributable equity is negative (-5,935.0 M USD)
ROIC 21.7 % Sector (7 companies) 93 17 % 23.2
Gross margin No data — — 17 % —
LTM gross profit: missing “Gross profit” for FY 31/12/2025, H1 30/06/2026, H1 30/06/2025
EBITDA margin 38.4 % Sector (7 companies) 79 17 % 19.6
Cash conversion 288.6 % Sector (7 companies) 93 17 % 23.2
Revenue growth 10.4 % Sector (7 companies) 93 17 % 23.2
Formulas and inputs

ROE: LTM attributable net income / Attributable equity at period end

LTM attributable net income
6,310.0
Attributable equity
-5,935.0

ROIC: LTM EBIT × (1 − notional tax rate) / (Total equity + Financial debt − Cash)

LTM EBIT
16,870.0
Total equity
-5,888.0
Financial debt
70,822.0
Cash and equivalents
6,569.0
Notional tax rate
0.2500

Gross margin: LTM gross profit / LTM revenue

EBITDA margin: LTM EBITDA / LTM revenue

LTM EBITDA
24,739.0
LTM revenue
64,386.0

Cash conversion: (LTM operating cash flow − LTM capex) / LTM net income attributable

LTM operating cash flow
19,507.0
LTM capital expenditure (capex)
1,297.0
LTM attributable net income
6,310.0

Revenue growth: LTM revenue / LTM revenue a year earlier − 1

LTM revenue
64,386.0
Prior-year LTM revenue
58,328.0

Amounts in euros

Market capitalisation No data
Enterprise value (EV) No data
LTM revenue 55,211 M EUR
LTM EBITDA 21,214 M EUR
Net debt 56,392 M EUR

Creditor view

FactorValueCompared with PercentileWeightContribution
Net debt/EBITDA 2.6x Sector (7 companies) 36 33 % 17.9
Interest coverage 8.5x Sector (7 companies) 36 33 % 17.9
Debt/equity Not meaningful — — 33 % —
Total equity is negative (-5,888.0 M USD)
Formulas and inputs

Net debt/EBITDA: (Financial debt − Cash) / LTM EBITDA

Financial debt
70,822.0
Cash and equivalents
6,569.0
LTM EBITDA
24,739.0

Interest coverage: LTM EBITDA / LTM interest expense

LTM EBITDA
24,739.0
LTM interest expense
2,916.0

Debt/equity: Financial debt / Total equity

Financial debt
70,822.0
Total equity
-5,888.0

Outstanding bonds

The loaded data contain no outstanding bonds of this company.

Alerts

No alerts in this run.

Screens

ScreenResultConditions
Moderate leverage Fails Net debt/EBITDA ≤ 2.5x: value: 2.6x
Interest coverage ≥ 5.0x: value: 8.5x

Annual history (millions of USD)

2023
FY 31/12/2023
2024
FY 31/12/2024
2025
FY 31/12/2025
Revenue54,31856,33461,160
EBITDA21,45517,52323,214
Attributable net income4,8634,2784,226
Free cash flow22,06217,83217,816
Net debt46,57161,62062,267

Each fiscal year is labelled with the calendar year in which most of its months fall.

The scores summarise metrics compared with similar companies, and the alerts point to specific facts. Nothing shown here is a recommendation to buy or sell.